Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro

Kano, Yasuhiko; Tanaka, Masaru; Akutsu, Miyuki; Mori, Kiyoshi; Yazawa, Yasuo; Mano, Hiroyuki; Furukawa, Yusuke
November 2009
Cancer Chemotherapy & Pharmacology;Nov2009, Vol. 64 Issue 6, p1129
Academic Journal
Pemetrexed and docetaxel show clinical activities against a variety of solid tumors including lung cancers. To identify the optimal schedule for combination, cytotoxic interactions between pemetrexed and docetaxel were studied at various schedules using three human lung cancer cell lines A-549, Lu-99, and SBC-5 in vitro. Cells were incubated with pemetrexed and docetaxel simultaneously for 24 or 120 h. Cells were also incubated with pemetrexed for 24 h, followed by a 24 h exposure to docetaxel, and vice versa. Growth inhibition was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cell cycle analysis. Cytotoxic interactions were evaluated by the isobologram method. Simultaneous exposure to pemetrexed and docetaxel for 24 and 120 h produced antagonistic effects in all three cell lines. Pemetrexed (24 h) followed by docetaxel (24 h) produced additive effects in A-549 cells and synergistic effects in Lu-99 and SBC-5 cells. Docetaxel followed by pemetrexed produced additive effects in A-549 and Lu-99 cells and antagonistic effects in SBC-5 cells. The results of cell cycle analysis were fully consistent with those of isobologram analysis, and provide the molecular basis of the sequence-dependent difference in cytotoxic interactions between the two agents. Sequential administration of pemetrexed followed by docetaxel may provide the greatest anti-tumor effects for this combination in the treatment of lung cancer.


Related Articles

  • Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs. Garcia, A Galan; Nedev, H; Bijian, K; Su, J; Alaoui-Jamali, M A; Saragovi, H U // Oncogene;5/16/2013, Vol. 32 Issue 20, p2527 

    Anthracyclines and taxanes have remarkable anticancer efficacy, but have poor selectivity and high toxicity. Targeted delivery of chemotherapeutics has emerged as a strategy to achieve higher drug levels at the tumor site, to spare noncancerous tissue and potentially to use lower systemic drug...

  • Activity of Anticancer Agents in a Three-Dimensional Cell Culture Model. Victor Sanjit Nirmalanandhan; Alicia Duren; Peter Hendricks; George Vielhauer; Gurusingham Sitta Sittampalam // Assay & Drug Development Technologies;Oct2010, Vol. 8 Issue 5, p581 

    AbstractCell-monolayer-based assays for chemotherapeutic drug discovery have proven to be highly artificial compared with physiological systems. The objective of this study was to culture cancer cells in a simple 3-dimensional (3D) collagen gel model to study the antiproliferative activity of...

  • Wogonin Has Multiple Anti-Cancer Effects by Regulating c-Myc/SKP2/Fbw7α and HDAC1/HDAC2 Pathways and Inducing Apoptosis in Human Lung Adenocarcinoma Cell Line A549. Chen, Xin-mei; Bai, Yang; Zhong, Yu-jian; Xie, Xiao-lin; Long, Han-wu; Yang, Yu-yin; Wu, Shi-gen; Jia, Qiang; Wang, Xiao-hua // PLoS ONE;Nov2013, Vol. 8 Issue 11, p1 

    Wogonin is a plant monoflavonoid which has been reported to inhibit cell growth and/or induce apoptosis in various tumors. The present study examined the apoptosis-inducing activity and underlying mechanism of action of wogonin in A549 cells. The results showed that wogonin was a potent...

  • Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies. Chinn, Danielle; Holland, William; Mack, Philip // Journal of Cancer Research & Clinical Oncology;Jul2014, Vol. 140 Issue 7, p1137 

    Purpose: Aurora kinases are key regulators of mitotic events. Dysfunction of these kinases can cause polyploidy and chromosomal instability, a contributor to tumorigenesis. MK-5108 is a potent inhibitor of Aurora A kinase that has shown preclinical potent activity in malignancies of breast,...

  • Apoptosis and Apoptosis-Based Therapy in Lung Cancer. Cheng-Xiong Xu; Hua Jin; Myung-Haing Cho // Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 9, p952 

    Apoptosis is natural process in the development and maintenance of multicellular organisms. However, tumor cells often have faulty apoptotic pathways. The defects of apoptosis are partially caused by mutation and aberrant expression of apoptotic proteins. The apoptosis inactivation is implicated...

  • Potential Anticancer Natural Product Against Human Lung Cancer Cells. Khorshid, Faten A. // Trends in Medical Research;2009, Vol. 4 Issue 1, p8 

    PM 701 has potential anticancer activity and it caused selective programmed cell death in lung cancer cells (A549) as described previously, this further study is aimed to present the cytotoxic effect of the lyophilized PM 701 and its fraction. Lyophilized PM 701 appears to have cytototic...

  • Anticancer efficacy of 5F in NNK-induced lung cancer development of A/J mice and human lung cancer cells. Ming-Yue Li; Leung, Jackie; Kong, Angel W. Y.; Nian Ci Liang; Kefeng Wu; Hsin, Michael K. Y.; Yi Feng Deng; Xianling Gong; Yingnian Lv; Mok, Tony S. K.; Underwood, Malcolm J.; Chen, George G. // Journal of Molecular Medicine;Dec2010, Vol. 88 Issue 12, p1265 

    The mechanism responsible for the apoptotic effect induced by ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid (5F) is not fully understood and its in vivo effect has not been tested. In this study, the effect and mechanism of 5F was investigated in cigarette smoking carcinogen...

  • Differential sensitivity to etoposide (VP-16)-induced S phase delay in a panel of small-cell lung carcinoma cell lines with G1/S phase checkpoint dysfunction. Souès, Sylvie; Wiltshire, Marie; Smith, Paul J.; Soués, S; Wiltshire, M; Smith, P J // Cancer Chemotherapy & Pharmacology;Feb2001, Vol. 47 Issue 2, p133 

    Purpose: The highly schedule-dependent cytotoxic agent etoposide (VP-16) is initially effective in the treatment of small-cell lung cancer (SCLC), particularly in multidrug combination chemotherapy. Heterogeneity in cellular sensitivity to cell cycle arrest may underpin the...

  • Sepantronium is a DNA damaging agent that synergizes with PLK1 inhibitor volasertib. Mei Hong; Mingqiang Ren; Silva, Jeane; Kennedy, Thomas; Choi, Justin; Cowell, John K.; Zhonglin Hao // American Journal of Cancer Research;2014, Vol. 4 Issue 2, p135 

    In a search for novel agents that boost the anti-neoplastic effects of polo-like kinase 1 (PLK1) inhibitor volasertib, we found that a sepantronium and volasertib combination at the nano mole concentration potently inhibited growth of various non-small cell lung cancer (NSCLC) cell lines than...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics